Education
About Us
Working with TipRanks
Follow Us
Beigene, Ltd. (ONC)
:ONC
ONC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$126.97 - $287.88
Previous CloseN/A
VolumeN/A
Average Volume (3M)525.82K
Market Cap
$29.21B
Enterprise Value$22.17B
Total Cash (Recent Filing)$2.63B
Total Debt (Recent Filing)$1.08B
Price to Earnings (P/E)―
Beta1.20
Next Earnings
May 01, 2025EPS Estimate
-0.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.13
Shares Outstanding98,684,654
10 Day Avg. Volume386,015
30 Day Avg. Volume525,818
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)7.06
Price to Cash Flow (P/CF)89.50
P/FCF Ratio72.30
Enterprise Value/Market Cap0.76
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit6.89
Enterprise Value/Ebitda-55.80
Forecast
1Y Price Target
$320.95Price Target Upside26.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceBeigene’s loss from operations narrowed significantly, reflecting improved financial performance.
Revenue GuidanceThe company provided total revenue guidance for 2025 in the range of $4.9-$5.3B, well ahead of analyst estimates of $4.6B.
Sales PerformanceBeiGene reported a blowout quarter exceeding analyst and consensus expectations, with Brukinsa overtaking Calquence in the U.S. market.
Bears Say
R&D And SG&A ExpensesBeigene’s R&D/SG&A expense rose by 10%/21% YoY, impacting the company's cost structure.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
ONC FAQ
What was Beigene, Ltd.’s price range in the past 12 months?
Beigene, Ltd. lowest stock price was $126.97 and its highest was $287.88 in the past 12 months.
What is Beigene, Ltd.’s market cap?
Beigene, Ltd.’s market cap is $29.21B.
When is Beigene, Ltd.’s upcoming earnings report date?
Beigene, Ltd.’s upcoming earnings report date is May 01, 2025 which is in 37 days.
How were Beigene, Ltd.’s earnings last quarter?
Beigene, Ltd. released its earnings results on Feb 27, 2025. The company reported -$1.43 earnings per share for the quarter, missing the consensus estimate of -$1.012 by -$0.418.
Is Beigene, Ltd. overvalued?
According to Wall Street analysts Beigene, Ltd.’s price is currently Undervalued.
Does Beigene, Ltd. pay dividends?
Beigene, Ltd. does not currently pay dividends.
What is Beigene, Ltd.’s EPS estimate?
Beigene, Ltd.’s EPS estimate is -0.42.
How many shares outstanding does Beigene, Ltd. have?
Beigene, Ltd. has 98,684,654 shares outstanding.
What happened to Beigene, Ltd.’s price movement after its last earnings report?
Beigene, Ltd. reported an EPS of -$1.43 in its last earnings report, missing expectations of -$1.012. Following the earnings report the stock price went up 7.483%.
Which hedge fund is a major shareholder of Beigene, Ltd.?
Currently, no hedge funds are holding shares in ONC
---
BeiGene Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$320.95 (26.76% Upside)
$320.95 (26.76% Upside)
Blogger Sentiment
Bullish
ONC Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 908.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $190.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 6.9%
Last 30 Days ▲ 13.8%
Last 30 Days ▲ 13.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
66.55%
12-Months-Change
Fundamentals
Return on Equity
-18.77%
Trailing 12-Months
Asset Growth
2.06%
Trailing 12-Months
Company Description
Beigene, Ltd.
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235) is a global biotechnology company focused on developing innovative molecularly targeted and immuno-oncology drug candidates for the treatment of cancer. The company is committed to delivering affordable and accessible medicines to patients worldwide. BeiGene's core products include Brukinsa (zanubrutinib), a BTK inhibitor, and tislelizumab, an anti-PD-1 antibody, among other oncology therapies. The company operates primarily within the biopharmaceutical sector, with research and development facilities in China, the United States, and Australia.
---
ONC Company Deck
---
ONC Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong financial performance and market leadership for BRUKINSA, along with robust R&D productivity. However, challenges remain in the competitive landscape and in achieving desired outcomes with fixed duration treatments. Overall, the positives significantly outweigh the negatives.Read More>---
ONC Stock 12 Month Forecast
Average Price Target
$320.95
▲(26.76% Upside)
Technical Analysis
Best Analysts Covering ONC
1 Year
1 Year Success Rate
13/14 ratings generated profit
1 Year Average Return
+22.52%
reiterated a buy rating last month
Copying Kelly Shi's trades and holding each position for 1 Year would result in 92.86% of your transactions generating a profit, with an average return of +22.52% per trade.
---